# Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut

> **NCT01275508** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Erlangen-Nürnberg Medical School** · enrollment: 25 (actual)

## Conditions studied

- Crohn's Disease

## Interventions

- **DRUG:** FITC-Adalimumab

## Key facts

- **NCT ID:** NCT01275508
- **Lead sponsor:** University of Erlangen-Nürnberg Medical School
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-01
- **Primary completion:** 2012-04
- **Final completion:** 2012-04
- **Target enrollment:** 25 (ACTUAL)
- **Last updated:** 2012-09-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01275508

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01275508, "Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01275508. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*